Stocks
STLN Drops 46% in Snapshot Despite Growth as Guidance Narrows
$STLN. Starling Oncology sold off after its quarterly update. Examine the mixed guidance changes and why stronger revenue does not settle the stock's valuation.
Read the story
$STLN. Starling Oncology sold off after its quarterly update. Examine the mixed guidance changes and why stronger revenue does not settle the stock's valuation.
Read the story
Stocks$AIRS. AirSculpt lowered its annual outlook after weaker procedure demand. Explore the earnings catalyst, refinancing and risks behind the AIRS selloff.